Walgreens Participation In 340B Program Probed By Sen. Grassley
This article was originally published in The Pink Sheet Daily
Executive Summary
Grassley suggests concern that the big pharmacy chain’s participation in the program may lead to diversion, in which drugs purchased at discounted 340B pricing are dispensed to insured individuals, allowing the pharmacy to profit from the difference in payments.